Analysts expect that Proteostasis Therapeutics Inc (NASDAQ:PTI) will post earnings of ($0.29) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Proteostasis Therapeutics’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.26). Proteostasis Therapeutics posted earnings per share of ($0.36) during the same quarter last year, which would indicate a positive year-over-year growth rate of 19.4%. The company is scheduled to report its next quarterly earnings report on Friday, March 13th.
According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.23) to ($1.18). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.61) to ($1.11). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Proteostasis Therapeutics.
Proteostasis Therapeutics (NASDAQ:PTI) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.25) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.15.
A number of equities analysts recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Proteostasis Therapeutics in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Proteostasis Therapeutics in a research note on Monday, December 23rd. Zacks Investment Research upgraded Proteostasis Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Wednesday, November 13th. ValuEngine upgraded Proteostasis Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $4.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, December 17th. Five investment analysts have rated the stock with a buy rating, Proteostasis Therapeutics has a consensus rating of “Buy” and a consensus price target of $6.75.
NASDAQ:PTI opened at $1.94 on Friday. Proteostasis Therapeutics has a 1 year low of $0.61 and a 1 year high of $4.72. The company has a market cap of $96.63 million, a price-to-earnings ratio of -1.20 and a beta of 0.29. The stock’s 50 day simple moving average is $2.55 and its two-hundred day simple moving average is $1.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.89 and a quick ratio of 6.89.
In other news, major shareholder Enterprise Associates 12 New sold 117,164 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $2.45, for a total value of $287,051.80. The transaction was disclosed in a filing with the SEC, which is available through this link. 19.80% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. A.R.T. Advisors LLC acquired a new position in Proteostasis Therapeutics during the second quarter worth $189,000. Jane Street Group LLC boosted its position in shares of Proteostasis Therapeutics by 445.5% in the 2nd quarter. Jane Street Group LLC now owns 175,050 shares of the company’s stock worth $171,000 after buying an additional 142,958 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Proteostasis Therapeutics in the 2nd quarter valued at about $150,000. Finally, Squarepoint Ops LLC raised its stake in Proteostasis Therapeutics by 62.4% during the third quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock valued at $38,000 after buying an additional 17,120 shares in the last quarter. 41.49% of the stock is currently owned by institutional investors.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Read More: What causes a recession?
Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.